Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy

<table>Mechanisms of actions of anakinra, canakinumab, gevokizumab, tocilizumab, ustekinumab, and rituximab, based on the different mechanisms of antagonizing cytokine receptors, cytokines, and cellular antigens.</table>

Mediators of Inflammation

fig1

Figure 1

Figure 1: Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy 